Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Duration: February 1, 2021
to
December 31, 2022
General Issues: Alcohol & Drug Abuse , Medicare/Medicaid
Spending: about $270,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives, Office of Natl Drug Control Policy (NDCP), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Substance Abuse & Mental Health Services Administration (SAMHSA), Drug Enforcement Administration (DEA), Justice - Dept of (DOJ)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2022
End SUD, Inc. dba End Substance Use Disorder in-house lobbying effort was terminated on Jan. 12, 2023
Original Filing: 301426532.xml
Lobbying Issues
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, End SUD, Inc. dba End Substance Use Disorder had in-house lobbyists. The report was filed on Oct. 11, 2022.
Original Filing: 301402761.xml
Lobbying Issues
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, End SUD, Inc. dba End Substance Use Disorder had in-house lobbyists. The report was filed on July 12, 2022.
Original Filing: 301379383.xml
Lobbying Issues
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, End SUD, Inc. dba End Substance Use Disorder had in-house lobbyists. The report was filed on April 12, 2022.
Original Filing: 301344986.xml
Lobbying Issues
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; Reducing Barriers to Substance Use Treatment Act, All Provisions (bill has not been reintroduced yet); U.S. Department of Health and Human Services, Overdose Prevention Strategy, All Provisions; Enforcement of Pharmacies and Wholesalers Providing Buprenorphine for Opioid Use Disorder.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, END SUD, INC. had in-house lobbyists. The report was filed on Jan. 18, 2022.
Original Filing: 301325360.xml
Lobbying Issues
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS.
U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER.
FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS.
H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS.
H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 955, S.285, THE MEDICAID REENTRY ACT, ALL PROVISIONS.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, END SUD, INC. had in-house lobbyists. The report was filed on Oct. 15, 2021.
Original Filing: 301300094.xml
Lobbying Issues
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER.
FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS.
H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS.
H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, END SUD, INC. had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301280938.xml
Lobbying Issues
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST PROVISIONS RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
End SUD, Inc. dba End Substance Use Disorder filed a lobbying registration on Feb. 11, 2022 for in-house lobbying efforts, effective Feb. 1, 2021.
Original Filing: 301341219.xml
Issue(s) they said they’d lobby about: H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS.
H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS.
H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED).
FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER.
FEDERAL OVERDOSE PREVENTION STRATEGY.
FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT.
OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER. .
1st Quarter, 2021
End SUD, Inc. dba End Substance Use Disorder filed a lobbying registration on Feb. 10, 2022 for in-house lobbying efforts, effective Feb. 1, 2021.
Original Filing: 301341160.xml
Issue(s) they said they’d lobby about: H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS.
H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS.
H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED).
FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER.
FEDERAL OVERDOSE PREVENTION STRATEGY.
FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT.
OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER. .
1st Quarter, 2021
In Q1, END SUD, INC. had in-house lobbyists. The report was filed on April 15, 2021.
Original Filing: 301253406.xml
Lobbying Issues
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
END SUD, INC. filed a lobbying registration on March 16, 2021 for in-house lobbying efforts, effective Feb. 1, 2021.
Original Filing: 301249661.xml
Issue(s) they said they’d lobby about: Mainstreaming Addiction Treatment Act (H.R. 1384, S. 445) and policies to end substance use disorder. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...